COPD Management Guidelines

Diagnosis and Classification

The American Thoracic Society recommends that COPD diagnosis requires three essential features: post-bronchodilator FEV1/FVC ratio <0.70, appropriate symptoms, and significant exposure to noxious stimuli such as cigarette smoking 1
The GOLD classification system categorizes patients into four groups (A, B, C, D) based on symptoms and exacerbation history, no longer using spirometric severity as the primary driver of treatment decisions 2, 3

For Group A patients, the American College of Chest Physicians recommends starting with a short-acting bronchodilator as needed for symptom relief 2
For Group B patients, the American College of Chest Physicians recommends initiating treatment with a long-acting bronchodilator, preferably LAMA over LABA 2
For Group C patients, the American College of Chest Physicians recommends starting with LAMA monotherapy as the preferred initial treatment 2
For Group D patients, the American College of Chest Physicians recommends initiating with LAMA + LABA combination therapy 2

The American Thoracic Society recommends that smoking cessation is the single most important intervention that influences the natural history of COPD 3
The American College of Chest Physicians recommends that patients in Groups B, C, and D with high symptom burden should participate in comprehensive pulmonary rehabilitation programs 2, 4
The Centers for Disease Control and Prevention recommends that all COPD patients should receive influenza vaccination annually 2, 4

The American College of Chest Physicians recommends that short-acting inhaled β2-agonists, with or without short-acting anticholinergics, are the initial bronchodilators for acute exacerbations 7, 8
The American College of Chest Physicians recommends that systemic corticosteroids improve lung function, oxygenation, and shorten recovery time and hospitalization duration 7, 8

The American Thoracic Society recommends that in selected patients with heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, bronchoscopic or surgical lung volume reduction may be considered 7, 9, 10
The International Society for Heart and Lung Transplantation recommends that referral criteria for lung transplantation include COPD with progressive disease, not a candidate for lung volume reduction, and severe pulmonary dysfunction 6, 8

The American Heart Association recommends that cardiovascular disease is highly prevalent and must be actively screened in COPD patients 5
The American Gastroenterological Association recommends that gastroesophageal reflux disease is an independent risk factor for COPD exacerbations 5